Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways

Yosef Yarden; Moshe Elkabets

doi:10.1007/978-3-319-67932-7

Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways

Yosef Yarden (Editor), Moshe Elkabets (Editor)

The Shraga Segal Department of Microbiology and Immunology

Ben-Gurion University of the Negev

Research output: Book/Report › Book › peer-review

Abstract

This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.

Original language	American English
Place of Publication	Cham
Publisher	Springer
Number of pages	242
Edition	1st ed. 2018
ISBN (Electronic)	9783319679327
ISBN (Print)	9783319679303
DOIs	https://doi.org/10.1007/978-3-319-67932-7
State	Published - 2018

Publication series

Name	Resistance to Targeted Anti-Cancer Therapeutics
Volume	15

ULI publications

uli
Cancer -- Research
Cancer research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/978-3-319-67932-7

Cite this

@book{2f2073fcd5f241c381bb3c68c51f23af,

title = "Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways",

abstract = "This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.",

editor = "Yosef Yarden and Moshe Elkabets",

note = "notValidatingIssn:2196-5501 ;",

year = "2018",

doi = "10.1007/978-3-319-67932-7",

language = "American English",

isbn = "9783319679303",

series = "Resistance to Targeted Anti-Cancer Therapeutics",

publisher = "Springer",

address = "Germany",

edition = "1st ed. 2018",

}

TY - BOOK

T1 - Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways

A2 - Yarden, Yosef

A2 - Elkabets, Moshe

N1 - notValidatingIssn:2196-5501 ;

PY - 2018

Y1 - 2018

N2 - This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.

AB - This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.

U2 - 10.1007/978-3-319-67932-7

DO - 10.1007/978-3-319-67932-7

M3 - Book

SN - 9783319679303

T3 - Resistance to Targeted Anti-Cancer Therapeutics

BT - Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways

PB - Springer

CY - Cham

ER -